logo
episode-header-image
May 28
4m 57s

Allianz Global Insurance Report 2026: Th...

Allianz Research
About this episode
The Allianz Global Insurance Report shows that global premiums rose by 7% to reach 6.9 trillion euros in 2025, adding 456 billion euros to the global premium pool. But looking ahead, there are some bigger forces shaping the future of the insurance industry. Join our AI assistants Aria and Bob to find out more. Read the full report: https://www.allianz.com/ ... Show More
Up next
Jul 10
Half-Time Outlook 2026-27: AI holds the score, growth slows to +2.5%
In our last episode before the summer break, Aria and Bob dive into Allianz Research's Half-Time Outlook for 2026-2027. How is the energy shock from the Middle East conflict playing out? Has inflation been knocked out? Tune in to find out! You can read the full report on our webs ... Show More
4m 32s
Jun 26
Ten years after Brexit: Resilience without revival
The UK is now looking for its seventh prime minister in 10 years after Keir Starmer’s resignation earlier this week. Interestingly, this week also marks 10 years since the Brexit vote, which roiled markets and divided forecasters. In this episode, Aria and Bob look at which proje ... Show More
5m 21s
Jun 12
How AI is rewiring global trade
AI-related trade has already grown from USD1trn in 2014 to USD3.8trn as of 2025, equivalent to 15% of all global trade. In this episode, we look at how AI is reshaping global trade, concentrating global power, supply chains and dependencies. This content was generated by AI with ... Show More
5m 19s
Recommended Episodes
Oct 2024
Hot shot: the wider promise of weight-loss jabs
<p>First they treated diabetes. Then obesity. Now <a href="https://www.economist.com/leaders/2024/10/24/its-not-just-obesity-drugs-like-ozempic-will-change-the-world?utm_campaign=a.io&utm_medium=audio.podcast.np&utm_source=theintelligence&utm_content=discovery.content.anonymous.t ... Show More
23m 58s
Sep 2023
2. The drug behind Europe's most valuable company
How much harm has been done by decades of governments investing too little? Is buy-now-pay-later causing misery or joy for young shoppers? Are supermarkets cutting prices fast enough? Is Novo Nordisk’s anti obesity wonder drug Semaglutide the most important pharmaceutical discove ... Show More
56m 39s
Dec 2023
Pfizer’s Second Gut Punch Shows Pitfalls of Weight-Loss Pills
 Bloomberg News Health Reporter Madison Muller explains how Pfizer’s second weight-loss setback this year is a warning sign that breaking into the lucrative obesity market isn’t going to be easy. Cory Klippsten, CEO at Swan Bitcoin, shares his crypto outlook for 2024. Benjamin Wo ... Show More
42m 33s
Aug 2023
Divergent Economic Outcomes: Japan, China, Europe and the US
A lively and informative discussion between Ayesha and Mayhem about the economic picture in Japan, Europe, and the US, as well as what we’re looking out for as we navigate the rest of 2023. Get full access to MacroVisor at macrovisor.substack.com/subscribe 
37m 52s